|
PIK3C2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.09832151654155E-14 |
| Normal-vs-Stage2 |
4.06509999995031E-06 |
| Normal-vs-Stage3 |
3.04201108747293E-14 |
| Normal-vs-Stage4 |
2.64233079860787E-14 |
| Stage1-vs-Stage2 |
2.493600E-01 |
| Stage1-vs-Stage3 |
6.165800E-02 |
| Stage1-vs-Stage4 |
1.004200E-03 |
| Stage2-vs-Stage3 |
2.552200E-02 |
| Stage2-vs-Stage4 |
2.056600E-03 |
| Stage3-vs-Stage4 |
1.719580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.52310000000244E-05 |
| Normal-vs-Asian |
8.19130319129613E-11 |
| Caucasian-vs-AfricanAmerican |
4.645000E-01 |
| Caucasian-vs-Asian |
4.542400E-01 |
| AfricanAmerican-vs-Asian |
2.444200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.49480469405717E-14 |
| Normal-vs-Female |
1.6251444634463E-12 |
| Male-vs-Female |
4.968600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.47124543051314E-12 |
| Normal-vs-Age(41-60Yrs) |
4.35207425653061E-14 |
| Normal-vs-Age(61-80Yrs) |
2.40241160298638E-12 |
| Normal-vs-Age(81-100Yrs) |
3.992600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.009800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.400200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.940000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.684400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.310800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.117600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.387000E-04 |
| Classical-VS-Follicular |
5.723800E-02 |
| Classical-VS-Other |
4.267200E-01 |
| Classical-VS-Normal |
9.73759961553355E-11 |
| Tall-VS-Follicular |
2.27229999999468E-05 |
| Tall-VS-Other |
4.437400E-01 |
| Tall-VS-Normal |
1.65178981603731E-12 |
| Follicular-VS-Other |
2.136800E-01 |
| Follicular-VS-Normal |
1.14490000002743E-06 |
| Other-VS-Normal |
5.811700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.223243728532E-12 |
| Normal-vs-N1 |
7.04536429196878E-12 |
| N0-vs-N1 |
7.182200E-02 |
|
|
